井上享先生の論文がTargeted Oncologyにアクセプトされました！
Congratulations !
One‑Week Inflammatory Kinetics After First‑Line Nivolumab Plus Ipilimumab in Metastatic Renal Cell Carcinoma: A Multicenter Landmark Analysis.
Inoue T, Numakura K, Osawa T, Naito S, Ishihara T, Ohba K, Ueda K, Sekine Y, Oki M, Naito H, Miyata H, Kikuchi H, Kobayashi S, Narita S, Tsuchiya N, Sugimoto M, Igawa T, Shin T.
Targeted Oncology.2026 https://doi.org/10.1007/s11523-026-01251-y